What is Charcot-Marie-Tooth (CMT) disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Charcot-Marie-Tooth disease (CMT) is an inherited neurological disorder that affects the peripheral nerves, causing muscle weakness, atrophy, and sensory loss primarily in the feet, legs, hands, and arms. This condition is characterized by a slow onset, typically presenting in childhood, and progressing from the lower limbs to more proximal muscles 1. The disease results from genetic mutations affecting proteins involved in the structure and function of peripheral nerves, leading to the gradual degeneration of the myelin sheath or axons that transmit signals between the brain and extremities.

Key Characteristics of CMT

  • Inherited neurological disorder
  • Affects peripheral nerves
  • Causes muscle weakness, atrophy, and sensory loss
  • Primarily affects the feet, legs, hands, and arms
  • Slow onset, typically presenting in childhood

Management and Treatment

There is no cure for CMT, but management focuses on maintaining function and preventing complications. Treatment typically includes physical therapy to preserve muscle strength and prevent contractures, occupational therapy to help with daily activities, and orthotic devices like ankle-foot braces to improve stability and walking 2, 3. Pain management may involve medications such as gabapentin, pregabalin, or amitriptyline for neuropathic pain. Regular monitoring by a neurologist is essential, as is genetic counseling for family planning. Some patients benefit from orthopedic surgery to correct foot deformities like high arches or hammertoes.

Recent Developments in Treatment

Recent research has highlighted the potential of disease-modifying therapies, including gene silencing, gene addition, and gene editing, although most treatments that reach clinical trials are drug treatments 4. Currently, only gene therapies for CMT2S have reached the clinical trial stage.

Quality of Life and Prognosis

The disease progresses slowly and varies in severity, but most people maintain a normal lifespan. CMT results from genetic mutations affecting proteins involved in the structure and function of peripheral nerves, leading to the gradual degeneration of the myelin sheath or axons that transmit signals between the brain and extremities. With proper management and treatment, individuals with CMT can improve their functional status and walking stability, and maintain a good quality of life 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.